Friday, 16 October 2026European Markets

LAVIDE HOLDING Stock Bullish Momentum With A 34% Rise In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of LAVIDE HOLDING (AEX-Index: LVIDE.AS) rose by a staggering 34.45% in 21 sessions from €0.24 to €0.32 at 05:11 EST on Tuesday, following the last session's downward trend. AEX-Index is sliding 0.48% to €768.98, following the last session's downward trend.

LAVIDE HOLDING's last close was €0.34, 36.8% below its 52-week high of €0.54.

About LAVIDE HOLDING

Lavide Holding N.V. does not have significant operations. Previously, it was engaged in the provision of integrated information technology solutions for medium to large-sized companies and organizations. The company was formerly known as Qurius N.V. and changed its name to Lavide Holding N.V. in July 2013. Lavide Holding N.V. was incorporated in 1998 and is based in Sluis, the Netherlands.

Earnings Per Share

As for profitability, LAVIDE HOLDING has a trailing twelve months EPS of €-0.04.

Volume

Today's last reported volume for LAVIDE HOLDING is 13436 which is 81.83% below its average volume of 4156.

Volatility

LAVIDE HOLDING's last week, last month's, and last quarter's current intraday variation average was 1.01%, 2.26%, and 6.98%.

LAVIDE HOLDING's highest amplitude of average volatility was 1.80% (last week), 5.82% (last month), and 6.98% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, LAVIDE HOLDING's stock is considered to be overbought (>=80).

Moving Average

LAVIDE HOLDING's worth is way above its 50-day moving average of €0.24 and below its 200-day moving average of €0.35.

More news about LAVIDE HOLDING (LVIDE.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com